Determination of antipyrine and metabolites in plasma of a patient with mild renal failure.
A method has been developed for the simultaneous determination of antipyrine and its three major metabolites in plasma of patients with renal failure. Plasma samples (500 microl) were hydrolyzed with beta-glucuronidase/aryl sulphatase. The compounds, after addition of sodium chloride, were extracted with chloroform:ethanol (90:10, v/v) in acidic medium. Chromatographic conditions comprise a C18 column, a mobile phase with 30% methanol and 70% 0.25N sodium acetate buffer (pH 5.0), a total run time of 10 minutes, and ultraviolet absorbance detection at 254 nm. Confidence limits showed 0.5 to 40.0 microg/ml(-1) linearity (r2 = 0.999); 0.1 microg/ml(-1) HMA, 0.05 microg/ml(-1) antipyrine and NORA, and 0.5 microg/ml(-1) OHA sensitivity and absolute recovery >95%. Interprecision and intraprecision expressed as coefficient of variation were <10% for all compounds investigated. The assay shows to be suitable for pharmacokinetics and drug metabolism studies after administration of a single oral dose of 500 mg of antipyrine to a patient with hypertension and chronic renal failure (CL(CR) = 34.17 ml/min(-1); 1.73 m(-2)).
Lanchote
V L
VL
Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Brazil.
Ping
W C
WC
Santos
S R
SR
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood* / Q000493:pharmacokinetics; D000983:Antipyrine / Q000031:analogs & derivatives / Q000097:blood* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D000077553:Edaravone; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications; D008657:Metabolic Clearance Rate; D012016:Reference Values
D000894:Anti-Inflammatory Agents, Non-Steroidal; C007983:4-hydroxyantipyrine; C031820:3-hydroxymethylantipyrine; D000077553:Edaravone; D000983:Antipyrine